Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...

News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...

If the past four decades have taught us anything about HIV, it's to adjust our expectations—despite enormous progress in ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two injections per year to one against HIV. "It is a hopeful step and the study data are ...

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential causes, biomarkers, and the significance of viral rebound. A virologist ...

As scientists gathered at the Conference for Retroviruses and Opportunistic Infections, or CROI, for meetings that run through Wednesday, they face an uncertain future. It was evident in who was ...

Ensitrelvir reduced transmission of SARS-CoV-2 by 67% when given to uninfected household contacts of a person with COVID-19 ...

Spotlight reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the ...

taking ensitrelvir within 72 hours of symptoms is effective at preventing infection and generally well tolerated, according ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Previous research has suggested an increased risk for neuropsychiatric symptoms in people living with HIV who are being ...

Injections of semaglutide were associated with significant improvement in cognitive function in people living with HIV (PWH), ...